National Drugs Management Scheme

National Drugs Management Scheme 

The National Drugs Management Scheme (NDMS) is a web based, centralised funding and reimbursement system for high cost drugs. This scheme is now in place within our acute hospitals for the purchase and provision of the approved drugs natalizumab (Tysabri®) and alemtuzumab (Lemtrada®) for Multiple Sclerosis (MS).

Although the system will initially focus on second line disease modifying medicines - natalizumab (Tysabri®) and alemtuzumab (Lemtrada®) for MS patients in the acute hospital setting, the list of drugs covered by the National Drugs Management Scheme may expand over time.

The primary goal is to ensure equitable access for all patients to specified high-cost drugs, regardless of their geographical location and to support hospitals in meeting the financial burden of providing these drugs to patients.

The Acute Hospitals Drugs Management Programme oversees the operational management of the scheme.

Contact: if you require any further information on the scheme.

The Primary Care Reimbursement Service (PCRS) on behalf of the Acute Hospital Division (AHD) facilitates all hospital reimbursement claims under the scheme.


NDMP Patient Information Leaflet